WhiteSwell Medical
Acute Decompensated Heart Failure Treatment
Company Overview
Snapshot
Founded in September 2014, WhiteSwell Medical operates with 11–50 employees. The company has raised $30 million across one funding round from two investors. In December 2018, WhiteSwell Medical secured $30 million in funding.
Business overview
WhiteSwell Medical is a science-driven company focused on improving the treatment of acute decompensated heart failure (ADHF), a major cause of repeat hospitalizations. The company is developing a minimally invasive, catheter-based approach designed to enhance the natural fluid-removal process of the lymphatic system, thereby more efficiently removing excess interstitial fluid in ADHF patients. It operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.
Strategic signal
In January 2022, WhiteSwell Medical expanded its senior management team with experienced executives. This move signals a strategic strengthening of leadership, likely in preparation for further development, clinical trials, or market entry for its catheter-based ADHF treatment. For investors, this indicates a company building out its operational capabilities and expertise to advance its innovative medical device.
Log in to access full profile ›Company Intelligence Q&A
- What is WhiteSwell Medical's primary focus?
- WhiteSwell Medical is dedicated to improving the treatment of acute decompensated heart failure (ADHF), a significant cause of repeat hospitalizations and emergency room visits.
- What is the core technology WhiteSwell Medical is developing?
- WhiteSwell Medical is developing a minimally invasive, catheter-based approach designed to more efficiently remove excess interstitial fluid in patients with ADHF by enhancing the natural fluid-removal process of the lymphatic system.
- When did WhiteSwell Medical strengthen its patent portfolio?
- In December 2020, WhiteSwell Medical strengthened its patent portfolio for the treatment of acute decompensated heart failure with a newly issued U.S. patent.
- Has WhiteSwell Medical made recent changes to its leadership?
- In January 2022, WhiteSwell Medical added experienced executives to its senior management team, enhancing its leadership and operational capabilities.
- How much capital has WhiteSwell Medical raised?
- WhiteSwell Medical has raised $30 million across one funding round. This round was joined by RA Capital Management and InCube Ventures in December 2018.